Structural insights into BMP receptors: Specificity, activation and inhibition

Cytokine and Growth Factor Reviews

Volumn 27, Issue , 2016, Pages 13-34

  Yadin, David ^a,b   Knaus, Petra ^a,b   Mueller, Thomas D ^c  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

BMP receptor activation; BMP receptor kinases and inhibitors; Ligand receptor interaction; Ligand receptor promiscuity; Protein protein recognition

Indexed keywords

6 [4 (1 PIPERAZINYL)PHENYL] 3 (4 QUINOLINYL)PYRAZOLO[1,5 A]PYRIMIDINE; ACTIVIN; ANTINEOPLASTIC AGENT; BONE MORPHOGENETIC PROTEIN RECEPTOR; DORSOMORPHIN; GROWTH DIFFERENTIATION FACTOR; INHIBIN; K 02288; LDN 212854; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; UNCLASSIFIED DRUG; BONE MORPHOGENETIC PROTEIN;

BINDING AFFINITY; CANCER CHEMOTHERAPY; CANCER INHIBITION; ENZYME INHIBITION; HUMAN; INTRACELLULAR SIGNALING; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN DOMAIN; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; RECEPTOR BINDING; REVIEW; ANIMAL; CHEMISTRY; METABOLISM; MYOSITIS OSSIFICANS; PATHOLOGY; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

ANIMALS; BONE MORPHOGENETIC PROTEIN RECEPTORS; BONE MORPHOGENETIC PROTEINS; HUMANS; MYOSITIS OSSIFICANS; SIGNAL TRANSDUCTION; SMAD PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84957440741     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2015.11.005     Document Type: Review

References (219)

1. Pelton R.W., Saxena B., Jones M., Moses H.L., Gold L.I. Immunohistochemical localization of TGF beta 1, TGF beta 2, and TGF beta 3 in the mouse embryo: expression patterns suggest multiple roles during embryonic development. J. Cell Biol. 1991, 115:1091-1105.
2. Kaartinen V., Voncken J.W., Shuler C., Warburton D., Bu D., Heisterkamp N., et al. Abnormal lung development and cleft palate in mice lacking TGF-beta 3 indicates defects of epithelial-mesenchymal interaction. Nat. Genet. 1995, 11:415-421.
3. Huber S., Schramm C., Lehr H.A., Mann A., Schmitt S., Becker C., et al. Cutting edge: TGF-beta signaling is required for the in vivo expansion and immunosuppressive capacity of regulatory CD4 + CD25 + T cells. J. Immunol. 2004, 173:6526-6531.
4. Pakyari M., Farrokhi A., Maharlooei M.K., Ghahary A. Critical role of transforming growth factor beta in different phases of wound healing. Adv. Wound Care (New Rochelle) 2013, 2:215-224.
5. Neuzillet C., Tijeras-Raballand A., Cohen R., Cros J., Faivre S., Raymond E., et al. Targeting the TGFbeta pathway for cancer therapy. Pharmacol. Ther. 2015, 147:22-31.
6. Cheng H., Jiang W., Phillips F.M., Haydon R.C., Peng Y., Zhou L., et al. Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs). J. Bone Joint Surg. Am. 2003, 85-A:1544-1552.
7. Zhao G.Q. Consequences of knocking out BMP signaling in the mouse. Genesis 2003, 35:43-56.
8. Bandyopadhyay A., Tsuji K., Cox K., Harfe B.D., Rosen V., Tabin C.J. Genetic analysis of the roles of BMP2, BMP4, and BMP7 in limb patterning and skeletogenesis. PLoS Genet. 2006, 2:e216.
9. Danesh S.M., Villasenor A., Chong D., Soukup C., Cleaver O. BMP and BMP receptor expression during murine organogenesis. Gene Expr. Patterns 2009, 9:255-265.
10. Zhang H., Bradley A. Mice deficient for BMP2 are nonviable and have defects in amnion/chorion and cardiac development. Development 1996, 122:2977-2986.
11. Winnier G., Blessing M., Labosky P.A., Hogan B.L. Bone morphogenetic protein-4 is required for mesoderm formation and patterning in the mouse. Genes Dev. 1995, 9:2105-2116.
12. Jena N., Martin-Seisdedos C., McCue P., Croce C.M. BMP7 null mutation in mice: developmental defects in skeleton, kidney, and eye. Exp. Cell Res. 1997, 230:28-37.
13. Kim R.Y., Robertson E.J., Solloway M.J. Bmp6 and Bmp7 are required for cushion formation and septation in the developing mouse heart. Dev. Biol. 2001, 235:449-466.
14. Solursh M., Langille R.M., Wood J., Sampath T.K. Osteogenic protein-1 is required for mammalian eye development. Biochem. Biophys. Res. Commun. 1996, 218:438-443.
15. Daluiski A., Engstrand T., Bahamonde M.E., Gamer L.W., Agius E., Stevenson S.L., et al. Bone morphogenetic protein-3 is a negative regulator of bone density. Nat. Genet. 2001, 27:84-88.
16. King J.A., Marker P.C., Seung K.J., Kingsley D.M. BMP5 and the molecular, skeletal, and soft-tissue alterations in short ear mice. Dev. Biol. 1994, 166:112-122.
17. Mikic B., Ferreira M.P., Battaglia T.C., Hunziker E.B. Accelerated hypertrophic chondrocyte kinetics in GDF-7 deficient murine tibial growth plates. J. Orthop. Res. 2008, 26:986-990.
18. Mikic B., Rossmeier K., Bierwert L. Identification of a tendon phenotype in GDF6 deficient mice. Anat. Rec. (Hoboken) 2009, 292:396-400.
19. Settle S.H., Rountree R.B., Sinha A., Thacker A., Higgins K., Kingsley D.M. Multiple joint and skeletal patterning defects caused by single and double mutations in the mouse Gdf6 and Gdf5 genes. Dev. Biol. 2003, 254:116-130.
20. Storm E.E., Huynh T.V., Copeland N.G., Jenkins N.A., Kingsley D.M., Lee S.J. Limb alterations in brachypodism mice due to mutations in a new member of the TGF beta-superfamily. Nature 1994, 368:639-643.
21. McPherron A.C., Lawler A.M., Lee S.J. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 1997, 387:83-90.
22. McPherron A.C., Lee S.J. Double muscling in cattle due to mutations in the myostatin gene. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:12457-12461.
23. Peng C., Mukai S.T. Activins and their receptors in female reproduction. Biochem. Cell Biol. 2000, 78:261-279.
24. Barakat B., Itman C., Mendis S.H., Loveland K.L. Activins and inhibins in mammalian testis development: new models, new insights. Mol. Cell Endocrinol. 2012, 359:66-77.
25. Phillips D.J., de Kretser D.M., Hedger M.P. Activin and related proteins in inflammation: not just interested bystanders. Cytokine Growth Factor Rev. 2009, 20:153-164.
26. Asashima M., Ariizumi T., Malacinski G.M. In vitro control of organogenesis and body patterning by activin during early amphibian development. Comp. Biochem. Physiol. B Biochem. Mol. Biol. 2000, 126:169-178.
27. Muenster U., Harrison C.A., Donaldson C., Vale W., Fischer W.H. An activin-A/C chimera exhibits activin and myostatin antagonistic properties. J. Biol. Chem. 2005, 280:36626-36632.
28. Cook R.W., Thompson T.B., Jardetzky T.S., Woodruff T.K. Molecular biology of inhibin action. Semin. Reprod. Med. 2004, 22:269-276.
29. Hamada H., Meno C., Watanabe D., Saijoh Y. Establishment of vertebrate left-right asymmetry. Nat. Rev. Genet. 2002, 3:103-113.
30. Chen C., Shen M.M. Two modes by which Lefty proteins inhibit nodal signaling. Curr. Biol. 2004, 14:618-624.
31. Saarma M. GDNF-a stranger in the TGF-beta superfamily. Eur. J. Biochem. 2000, 267:6968-6971.
32. Airaksinen M.S., Titievsky A., Saarma M. GDNF family neurotrophic factor signaling: four masters, one servant?. Mol. Cell Neurosci. 1999, 13:313-325.
33. Strelau J., Sullivan A., Bottner M., Lingor P., Falkenstein E., Suter-Crazzolara C., et al. Growth/differentiation factor-15/macrophage inhibitory cytokine-1 is a novel trophic factor for midbrain dopaminergic neurons in vivo. J. Neurosci. 2000, 20:8597-8603.
34. Corre J., Hebraud B., Bourin P. Concise review: growth differentiation factor 15 in pathology: a clinical role?. Stem Cells Transl. Med. 2013, 2:946-952.
35. Visser J.A. AMH signaling: from receptor to target gene. Mol. Cell Endocrinol. 2003, 211:65-73.
36. Colgrave M.L., Craik D.J. Thermal, chemical, and enzymatic stability of the cyclotide kalata B1: the importance of the cyclic cystine knot. Biochemistry 2004, 43:5965-5975.
37. Rosen V., Wozney J.M., Wang E.A., Cordes P., Celeste A., McQuaid D., et al. Purification and molecular cloning of a novel group of BMPs and localization of BMP mRNA in developing bone. Connect Tissue Res. 1989, 20:313-319.
38. Urist M.R., Huo Y.K., Brownell A.G., Hohl W.M., Buyske J., Lietze A., et al. Purification of bovine bone morphogenetic protein by hydroxyapatite chromatography. Proc. Natl. Acad. Sci. U. S. A. 1984, 81:371-375.
39. Sun P.D., Davies D.R. The cystine-knot growth-factor superfamily. Ann. Rev. Biophys. Biomol. Struct. 1995, 24:269-292.
40. Hearn M.T., Gomme P.T. Molecular architecture and biorecognition processes of the cystine knot protein superfamily: part I. The glycoprotein hormones. J. Mol. Recognit. 2000, 13:223-278.
41. Nolan K., Thompson T.B. The DAN family: modulators of TGF-beta signaling and beyond. Protein Sci. 2014, 23:999-1012.
42. McIntosh C.J., Lun S., Lawrence S., Western A.H., McNatty K.P., Juengel J.L. The proregion of mouse BMP15 regulates the cooperative interactions of BMP15 and GDF9. Biol. Reprod. 2008, 79:889-896.
43. Pulkki M.M., Mottershead D.G., Pasternack A.H., Muggalla P., Ludlow H., van Dinther M., et al. A covalently dimerized recombinant human bone morphogenetic protein-15 variant identifies bone morphogenetic protein receptor type 1B as a key cell surface receptor on ovarian granulosa cells. Endocrinology 2012, 153:1509-1518.
44. Dong J., Albertini D.F., Nishimori K., Kumar T.R., Lu N., Matzuk M.M. Growth differentiation factor-9 is required during early ovarian folliculogenesis. Nature 1996, 383:531-535.
45. Laitinen M., Vuojolainen K., Jaatinen R., Ketola I., Aaltonen J., Lehtonen E., et al. A novel growth differentiation factor-9 (GDF-9) related factor is co-expressed with GDF-9 in mouse oocytes during folliculogenesis. Mech. Dev. 1998, 78:135-140.
46. Juengel J.L., Bodensteiner K.J., Heath D.A., Hudson N.L., Moeller C.L., Smith P., et al. Physiology of GDF9 and BMP15 signalling molecules. Anim. Reprod. Sci. 2004, 82-83:447-460.
47. McNatty K.P., Juengel J.L., Reader K.L., Lun S., Myllymaa S., Lawrence S.B., et al. Bone morphogenetic protein 15 and growth differentiation factor 9 co-operate to regulate granulosa cell function. Reproduction 2005, 129:473-480.
48. Mottershead D.G., Harrison C.A., Mueller T.D., Stanton P.G., Gilchrist R.B., McNatty K.P. Growth differentiation factor 9:bone morphogenetic protein 15 (GDF9:BMP15) synergism and protein heterodimerization. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:E2257.
49. Peng J., Li Q., Wigglesworth K., Rangarajan A., Kattamuri C., Peterson R.T., et al. Growth differentiation factor 9:bone morphogenetic protein 15 heterodimers are potent regulators of ovarian functions. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:E776-E785.
50. Mottershead D.G., Sugimura S., Al-Musawi S.L., Li J.J., Richani D., White M.A., et al. Cumulin, an oocyte-secreted heterodimer of the transforming growth factor-beta family, is a potent activator of granulosa cells and improves oocyte quality. J. Biol. Chem. 2015.
51. Kunnapuu J., Tauscher P.M., Tiusanen N., Nguyen M., Loytynoja A., Arora K., et al. Cleavage of the Drosophila screw prodomain is critical for a dynamic BMP morphogen gradient in embryogenesis. Dev. Biol. 2014, 389:149-159.
52. O'Connor M.B., Umulis D., Othmer H.G., Blair S.S. Shaping BMP morphogen gradients in the Drosophila embryo and pupal wing. Development 2006, 133:183-193.
53. Schmid B., Furthauer M., Connors S.A., Trout J., Thisse B., Thisse C., et al. Equivalent genetic roles for bmp7/snailhouse and bmp2b/swirl in dorsoventral pattern formation. Development 2000, 127:957-967.
54. Shimmi O., Umulis D., Othmer H., O'Connor M.B. Facilitated transport of a Dpp/Scw heterodimer by Sog/Tsg leads to robust patterning of the Drosophila blastoderm embryo. Cell 2005, 120:873-886.
55. Sampath T.K., Coughlin J.E., Whetstone R.M., Banach D., Corbett C., Ridge R.J., et al. Bovine osteogenic protein is composed of dimers of OP-1 and BMP-2A, two members of the transforming growth factor-beta superfamily. J. Biol. Chem. 1990, 265:13198-13205.
56. Aono A., Hazama M., Notoya K., Taketomi S., Yamasaki H., Tsukuda R., et al. Potent ectopic bone-inducing activity of bone morphogenetic protein-4/7 heterodimer. Biochem. Biophys. Res. Commun. 1995, 210:670-677.
57. Kusumoto K., Bessho K., Fujimura K., Akioka J., Ogawa Y., Iizuka T. Comparison of ectopic osteoinduction in vivo by recombinant human BMP-2 and recombinant Xenopus BMP-4/7 heterodimer. Biochem. Biophys. Res. Commun. 1997, 239:575-579.
58. Dubois C.M., Laprise M.H., Blanchette F., Gentry L.E., Leduc R. Processing of transforming growth factor beta 1 precursor by human furin convertase. J. Biol. Chem. 1995, 270:10618-10624.
59. Constam D.B. Regulation of TGFbeta and related signals by precursor processing. Semin. Cell Dev. Biol. 2014, 32:85-97.
60. Molloy S.S., Thomas L., VanSlyke J.K., Stenberg P.E., Thomas G. Intracellular trafficking and activation of the furin proprotein convertase: localization to the TGN and recycling from the cell surface. EMBO J. 1994, 13:18-33.
61. Seidah N.G., Mayer G., Zaid A., Rousselet E., Nassoury N., Poirier S., et al. The activation and physiological functions of the proprotein convertases. Int. J. Biochem. Cell Biol. 2008, 40:1111-1125.
62. Akiyama T., Marques G., Wharton K.A. A large bioactive BMP ligand with distinct signaling properties is produced by alternative proconvertase processing. Sci. Signal. 2012, 5:ra28.
63. Shi M., Zhu J., Wang R., Chen X., Mi L., Walz T., et al. Latent TGF-beta structure and activation. Nature 2011, 474:343-349.
64. Bessa P.C., Cerqueira M.T., Rada T., Gomes M.E., Neves N.M., Nobre A., et al. Expression, purification and osteogenic bioactivity of recombinant human BMP-4, -9, -10, -11 and -14. Protein Expr. Purif. 2009, 63:89-94.
65. Honda J., Andou H., Mannen T., Sugimoto S. Direct refolding of recombinant human growth differentiation factor 5 for large-scale production process. J. Biosci. Bioeng. 2000, 89:582-589.
66. von Einem S., Schwarz E., Rudolph R. A novel TWO-STEP renaturation procedure for efficient production of recombinant BMP-2. Protein Expr. Purif. 2010, 73:65-69.
67. Gray A.M., Mason A.J. Requirement for activin A and transforming growth factor-beta 1 pro-regions in homodimer assembly. Science 1990, 247:1328-1330.
68. Kuhfahl S., Hauburger A., Thieme T., Groppe J., Ihling C., Tomic S., et al. Identification of a core domain within the proregion of bone morphogenetic proteins that interacts with the dimeric, mature domain. Biochem. Biophys. Res. Commun. 2011, 408:300-305.
69. Kuhfahl S., Schwarz E. A core domain of the BMP2 proregion is sufficient for the biogenesis of mature homodimeric growth factor. Biol. Chem. 2015, 396:215-223.
70. Wakefield L.M., Smith D.M., Broz S., Jackson M., Levinson A.D. Sporn MB. Recombinant TGF-beta 1 is synthesized as a two-component latent complex that shares some structural features with the native platelet latent TGF-beta 1 complex. Growth Factors 1989, 1:203-218.
71. Lawrence D.A., Pircher R., Jullien P. Conversion of a high molecular weight latent beta-TGF from chicken embryo fibroblasts into a low molecular weight active beta-TGF under acidic conditions. Biochem. Biophys. Res. Commun. 1985, 133:1026-1034.
72. Lyons R.M., Keski-Oja J., Moses H.L. Proteolytic activation of latent transforming growth factor-beta from fibroblast-conditioned medium. J. Cell Biol. 1988, 106:1659-1665.
73. Annes J.P., Munger J.S., Rifkin D.B. Making sense of latent TGFbeta activation. J. Cell Sci. 2003, 116:217-224.
74. Keski-Oja J., Koli K., von Melchner H. TGF-beta activation by traction. Trends Cell Biol. 2004, 14:657-659.
75. Ge G., Hopkins D.R., Ho W.B., Greenspan D.S. GDF11 forms a bone morphogenetic protein 1-activated latent complex that can modulate nerve growth factor-induced differentiation of PC12 cells. Mol. Cell Biol. 2005, 25:5846-5858.
76. Sengle G., Ono R.N., Sasaki T., Sakai L.Y. Prodomains of transforming growth factor beta (TGFbeta) superfamily members specify different functions: extracellular matrix interactions and growth factor bioavailability. J. Biol. Chem. 2011, 286:5087-5099.
77. Wolfman N.M., McPherron A.C., Pappano W.N., Davies M.V., Song K., Tomkinson K.N., et al. Activation of latent myostatin by the BMP-1/tolloid family of metalloproteinases. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:15842-15846.
78. Hauburger A., von E., inem S., Schwaerzer G.K., Buttstedt A., Zebisch M., Schraml M., et al. The pro-form of BMP-2 interferes with BMP-2 signalling by competing with BMP-2 for IA receptor binding. FEBS J. 2009, 276:6386-6398.
79. Hillger F., Herr G., Rudolph R., Schwarz E. Biophysical comparison of BMP-2, ProBMP-2, and the free pro-peptide reveals stabilization of the pro-peptide by the mature growth factor. J. Biol. Chem. 2005, 280:14974-14980.
80. Mi L.Z., Brown C.T., Gao Y., Tian Y., Le V.Q., Walz T., et al. Structure of bone morphogenetic protein 9 procomplex. Proc. Natl. Acad. Sci. U. S. A. 2015, 112:3710-3715.
81. Bailly S., Brand C., Chambaz E.M., Feige J.J. Analysis of small latent transforming growth factor-beta complex formation and dissociation by surface plasmon resonance. Absence of direct interaction with thrombospondins. J. Biol. Chem. 1997, 272:16329-16334.
82. De Crescenzo G., Grothe S., Zwaagstra J., Tsang M., O'Connor-McCourt M.D. Real-time monitoring of the interactions of transforming growth factor-beta (TGF-beta) isoforms with latency-associated protein and the ectodomains of the TGF-beta type II and III receptors reveals different kinetic models and stoichiometries of binding. J. Biol. Chem. 2001, 276:29632-29643.
83. Miller D.M., Ogawa Y., Iwata K.K., ten Dijke P., Purchio A.F., Soloff M.S., et al. Characterization of the binding of transforming growth factor-beta 1, -beta 2, and -beta 3 to recombinant beta 1-latency-associated peptide. Mol. Endocrinol. 1992, 6:694-702.
84. Gazzerro E., Canalis E. Bone morphogenetic proteins and their antagonists. Rev. Endocr. Metab. Disord. 2006, 7:51-65.
85. Massague J. TGF-beta signal transduction. Ann. Rev. Biochem. 1998, 67:753-791.
86. Miyazono K., Kamiya Y., Morikawa M. Bone morphogenetic protein receptors and signal transduction. J. Biochem. 2010, 147:35-51.
87. Zhang Y.E. Non-Smad pathways in TGF-beta signaling. Cell Res. 2009, 19:128-139.
88. Nohe A., Hassel S., Ehrlich M., Neubauer F., Sebald W., Henis Y.I., et al. The mode of bone morphogenetic protein (BMP) receptor oligomerization determines different BMP-2 signaling pathways. J. Biol. Chem. 2002, 277:5330-5338.
89. Wrana J.L., Attisano L., Carcamo J., Zentella A., Doody J., Laiho M., et al. TGF beta signals through a heteromeric protein kinase receptor complex. Cell 1992, 71:1003-1014.
90. Liu F., Ventura F., Doody J., Massague J. Human type II receptor for bone morphogenic proteins (BMPs): extension of the two-kinase receptor model to the BMPs. Mol. Cell Biol. 1995, 15:3479-3486.
91. Nohno T., Ishikawa T., Saito T., Hosokawa K., Noji S., Wolsing D.H., et al. Identification of a human type II receptor for bone morphogenetic protein-4 that forms differential heteromeric complexes with bone morphogenetic protein type I receptors. J. Biol. Chem. 1995, 270:22522-22526.
92. Luo K., Lodish H.F. Signaling by chimeric erythropoietin-TGF-beta receptors: homodimerization of the cytoplasmic domain of the type I TGF-beta receptor and heterodimerization with the type II receptor are both required for intracellular signal transduction. EMBO J. 1996, 15:4485-4496.
93. Luo K., Lodish H.F. Positive and negative regulation of type II TGF-beta receptor signal transduction by autophosphorylation on multiple serine residues. EMBO J. 1997, 16:1970-1981.
94. Chen R.H., Derynck R. Homomeric interactions between type II transforming growth factor-beta receptors. J. Biol. Chem. 1994, 269:22868-22874.
95. Gilboa L., Wells R.G., Lodish H.F., Henis Y.I. Oligomeric structure of type I and type II transforming growth factor beta receptors: homodimers form in the ER and persist at the plasma membrane. J. Cell Biol. 1998, 140:767-777.
96. Henis Y.I., Moustakas A., Lin H.Y., Lodish H.F. The types II and III transforming growth factor-beta receptors form homo-oligomers. J. Cell Biol. 1994, 126:139-154.
97. Gilboa L., Nohe A., Geissendorfer T., Sebald W., Henis Y.I., Knaus P. Bone morphogenetic protein receptor complexes on the surface of live cells: a new oligomerization mode for serine/threonine kinase receptors. Mol. Biol. Cell 2000, 11:1023-1035.
98. Marom B., Heining E., Knaus P., Henis Y.I. Formation of stable homomeric and transient heteromeric bone morphogenetic protein (BMP) receptor complexes regulates Smad protein signaling. J. Biol. Chem. 2011, 286:19287-19296.
99. Hassel S., Schmitt S., Hartung A., Roth M., Nohe A., Petersen N., et al. Initiation of Smad-dependent and Smad-independent signaling via distinct BMP-receptor complexes. J Bone Joint Surg Am. 2003, 85-A(Suppl. 3):44-51.
100. Knaus P., Sebald W. Cooperativity of binding epitopes and receptor chains in the BMP/TGFbeta superfamily. Biol. Chem. 2001, 382:1189-1195.
101. Healey E.G., Bishop B., Elegheert J., Bell C.H., Padilla-Parra S., Siebold C. Repulsive guidance molecule is a structural bridge between neogenin and bone morphogenetic protein. Nat. Struct. Mol. Biol. 2015, 22:458-465.
102. Mueller T.D. RGM co-receptors add complexity to BMP signaling. Nat. Struct. Mol. Biol. 2015, 22:439-440.
103. Hartung A., Bitton-Worms K., Rechtman M.M., Wenzel V., Boergermann J.H., Hassel S., et al. Different routes of bone morphogenic protein (BMP) receptor endocytosis influence BMP signaling. Mol. Cell Biol. 2006, 26:7791-7805.
104. Guzman A., Zelman-Femiak M., Boergermann J.H., Paschkowsky S., Kreuzaler P.A., Fratzl P., et al. SMAD versus non-SMAD signaling is determined by lateral mobility of bone morphogenetic protein (BMP) receptors. J. Biol. Chem. 2012, 287:39492-39504.
105. Hiepen C., Benn A., Denkis A., Lukonin I., Weise C., Boergermann J.H., et al. BMP2-induced chemotaxis requires PI3K p55gamma/p110alpha-dependent phosphatidylinositol (3,4,5)-triphosphate production and LL5beta recruitment at the cytocortex. BMC Biol. 2014, 12:43.
106. Josso N., di Clemente N., Gouedard L. Anti-Mullerian hormone and its receptors. Mol. Cell Endocrinol. 2001, 179:25-32.
107. Derynck R., Chen R.H., Ebner R., Filvaroff E.H., Lawler S. An emerging complexity of receptors for transforming growth factor-beta. Princess Takamatsu Symp. 1994, 24:264-275.
108. Heinecke K., Seher A., Schmitz W., Mueller T.D., Sebald W., Nickel J. Receptor oligomerization and beyond: a case study in bone morphogenetic proteins. BMC Biol. 2009, 7:59.
109. Allendorph G.P., Isaacs M.J., Kawakami Y. Izpisua Belmonte JC, Choe S. BMP-3 and BMP-6 structures illuminate the nature of binding specificity with receptors. Biochemistry 2007, 46:12238-12247.
110. Cheng S.K., Olale F., Bennett J.T., Brivanlou A.H., Schier A.F. EGF-CFC proteins are essential coreceptors for the TGF-beta signals Vg1 and GDF1. Genes Dev. 2003, 17:31-36.
111. Sako D., Grinberg A.V., Liu J., Davies M.V., Castonguay R., Maniatis S., et al. Characterization of the ligand binding functionality of the extracellular domain of activin receptor type IIb. J. Biol. Chem. 2010, 285:21037-21048.
112. Brown M.A., Zhao Q., Baker K.A., Naik C., Chen C., Pukac L., et al. Crystal structure of BMP-9 and functional interactions with pro-region and receptors. J. Biol. Chem. 2005, 280:25111-25118.
113. Moore R.K., Otsuka F., Shimasaki S. Molecular basis of bone morphogenetic protein-15 signaling in granulosa cells. J. Biol. Chem. 2003, 278:304-310.
114. Vitt U.A., Mazerbourg S., Klein C., Hsueh A.J. Bone morphogenetic protein receptor type II is a receptor for growth differentiation factor-9. Biol. Reprod. 2002, 67:473-480.
115. Hart P.J., Deep S., Taylor A.B., Shu Z., Hinck C.S., Hinck A.P. Crystal structure of the human TbetaR2 ectodomain-TGF-beta3 complex. Nat. Struct. Biol. 2002, 9:203-208.
116. Greenwald J., Groppe J., Gray P., Wiater E., Kwiatkowski W., Vale W., et al. The BMP7/ActRII extracellular domain complex provides new insights into the cooperative nature of receptor assembly. Mol. Cell 2003, 11:605-617.
117. Kirsch T., Nickel J., Sebald W. BMP-2 antagonists emerge from alterations in the low-affinity binding epitope for receptor BMPR-II. EMBO J. 2000, 19:3314-3324.
118. Thompson T.B., Woodruff T.K., Jardetzky T.S. Structures of an ActRIIB:activin A complex reveal a novel binding mode for TGF-beta ligand:receptor interactions. EMBO J. 2003, 22:1555-1566.
119. Baardsnes J., Hinck C.S., Hinck A.P., O'Connor-McCourt M.D. TbetaR-II discriminates the high- and low-affinity TGF-beta isoforms via two hydrogen-bonded ion pairs. Biochemistry 2009, 48:2146-2155.
120. Lopez-Casillas F., Wrana J.L., Massague J. Betaglycan presents ligand to the TGF beta signaling receptor. Cell 1993, 73:1435-1444.
121. Allendorph G.P., Vale W.W., Choe S. Structure of the ternary signaling complex of a TGF-beta superfamily member. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:7643-7648.
122. Weber D., Kotzsch A., Nickel J., Harth S., Seher A., Mueller U., et al. A silent H-bond can be mutationally activated for high-affinity interaction of BMP-2 and activin type IIB receptor. BMC Struct. Biol. 2007, 7:6.
123. Clackson T., Wells J.A. A hot spot of binding energy in a hormone-receptor interface. Science 1995, 267:383-386.
124. Greenwald J., Vega M.E., Allendorph G.P., Fischer W.H., Vale W., Choe S. A flexible activin explains the membrane-dependent cooperative assembly of TGF-beta family receptors. Mol. Cell 2004, 15:485-489.
125. Townson S.A., Martinez-Hackert E., Greppi C., Lowden P., Sako D., Liu J., et al. Specificity and structure of a high affinity activin receptor-like kinase 1 (ALK1) signaling complex. J. Biol. Chem. 2012, 287:27313-27325.
126. Hassel S., Eichner A., Yakymovych M., Hellman U., Knaus P., Souchelnytskyi S. Proteins associated with type II bone morphogenetic protein receptor (BMPR-II) and identified by two-dimensional gel electrophoresis and mass spectrometry. Proteomics 2004, 4:1346-1358.
127. Rosenzweig B.L., Imamura T., Okadome T., Cox G.N., Yamashita H., ten Dijke P., et al. Cloning and characterization of a human type II receptor for bone morphogenetic proteins. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:7632-7636.
128. Leyton P.A., Beppu H., Pappas A., Martyn T.M., Derwall M., Baron D.M., et al. Deletion of the sequence encoding the tail domain of the bone morphogenetic protein type 2 receptor reveals a bone morphogenetic protein 7-specific gain of function. PLoS One 2013, 8:e76947.
129. Machado R.D., Aldred M.A., James V., Harrison R.E., Patel B., Schwalbe E.C., et al. Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension. Hum. Mutat. 2006, 27:121-132.
130. Schwappacher R., Weiske J., Heining E., Ezerski V., Marom B., Henis Y.I., et al. Novel crosstalk to BMP signalling: cGMP-dependent kinase I modulates BMP receptor and Smad activity. EMBO J. 2009, 28:1537-1550.
131. Foletta V.C., Lim M.A., Soosairajah J., Kelly A.P., Stanley E.G., Shannon M., et al. Direct signaling by the BMP type II receptor via the cytoskeletal regulator LIMK1. J. Cell Biol. 2003, 162:1089-1098.
132. Lee-Hoeflich S.T., Causing C.G., Podkowa M., Zhao X., Wrana J.L., Attisano L. Activation of LIMK1 by binding to the BMP receptor, BMPRII, regulates BMP-dependent dendritogenesis. EMBO J. 2004, 23:4792-4801.
133. Hassel S., Yakymovych M., Hellman U., Ronnstrand L., Knaus P., Souchelnytskyi S. Interaction and functional cooperation between the serine/threonine kinase bone morphogenetic protein type II receptor with the tyrosine kinase stem cell factor receptor. J. Cell. Physiol. 2006, 206:457-467.
134. Babu M.M., Kriwacki R.W., Pappu R.V. Structural biology. Versatility from protein disorder. Science 2012, 337:1460-1461.
135. Nguyen Ba A.N., Yeh B.J., van Dyk D., Davidson A.R., Andrews B.J., Weiss E.L., et al. Proteome-wide discovery of evolutionary conserved sequences in disordered regions. Sci. Signal. 2012, 5:rs1.
136. Aramaki T., Sasai N., Yakura R., Sasai Y. Jiraiya attenuates BMP signaling by interfering with type II BMP receptors in neuroectodermal patterning. Dev. Cell 2010, 19:547-561.
137. Lemmon M.A., Schlessinger J., Ferguson K.M. The EGFR family: not so prototypical receptor tyrosine kinases. Cold Spring Harbor Perspect. Biol. 2014, 6:a020768.
138. Olsen O.E., Wader K.F., Hella H., Mylin A.K., Turesson I., Nesthus I., et al. Activin A inhibits BMP-signaling by binding ACVR2A and ACVR2B. Cell Commun. Signal. 2015, 13:27.
139. Lo R.S., Chen Y.G., Shi Y., Pavletich N.P., Massague J. The L3 loop: a structural motif determining specific interactions between SMAD proteins and TGF-beta receptors. EMBO J. 1998, 17:996-1005.
140. Persson U., Izumi H., Souchelnytskyi S., Itoh S., Grimsby S., Engstrom U., et al. The L45 loop in type I receptors for TGF-beta family members is a critical determinant in specifying Smad isoform activation. FEBS Lett. 1998, 434:83-87.
141. Shi Y., Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003, 113:685-700.
142. Derynck R., Zhang Y.E. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003, 425:577-584.
143. Zhang Y., Feng X., We R., Derynck R. Receptor-associated Mad homologues synergize as effectors of the TGF-beta response. Nature 1996, 383:168-172.
144. Oh S.P., Seki T., Goss K.A., Imamura T., Yi Y., Donahoe P.K., et al. Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:2626-2631.
145. Goumans M.J., Valdimarsdottir G., Itoh S., Rosendahl A., Sideras P., ten Dijke P. Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO J. 2002, 21:1743-1753.
146. Mahlawat P., Ilangovan U., Biswas T., Sun L.Z., Hinck A.P. Structure of the Alk1 extracellular domain and characterization of its bone morphogenetic protein (BMP) binding properties. Biochemistry 2012, 51:6328-6341.
147. van Caam A., Blaney Davidson E., Garcia de Vinuesa A., van Geffen E., van den Berg W., Goumans M.J., et al. The high affinity ALK1-ligand BMP9 induces a hypertrophy-like state in chondrocytes that is antagonized by TGFbeta1. Osteoarthr. Cartil. 2015, 23:985-995.
148. Willis S.A., Zimmerman C.M., Li L.I., Mathews L.S. Formation and activation by phosphorylation of activin receptor complexes. Mol. Endocrinol. 1996, 10:367-379.
149. Reissmann E., Jornvall H., Blokzijl A., Andersson O., Chang C., Minchiotti G., et al. The orphan receptor ALK7 and the Activin receptor ALK4 mediate signaling by Nodal proteins during vertebrate development. Genes Dev. 2001, 15:2010-2022.
150. Rebbapragada A., Benchabane H., Wrana J.L., Celeste A.J., Attisano L. Myostatin signals through a transforming growth factor beta-like signaling pathway to block adipogenesis. Mol. Cell Biol. 2003, 23:7230-7242.
151. Tsuchida K., Nakatani M., Yamakawa N., Hashimoto O., Hasegawa Y., Sugino H. Activin isoforms signal through type I receptor serine/threonine kinase ALK7. Mol. Cell Endocrinol. 2004, 220:59-65.
152. Andersson O., Korach-Andre M., Reissmann E., Ibanez C.F., Bertolino P. Growth/differentiation factor 3 signals through ALK7 and regulates accumulation of adipose tissue and diet-induced obesity. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:7252-7256.
153. Dragovic R.A., Ritter L.J., Schulz S.J., Amato F., Thompson J.G., Armstrong D.T., et al. Oocyte-secreted factor activation of SMAD 2/3 signaling enables initiation of mouse cumulus cell expansion. Biol. Reprod. 2007, 76:848-857.
154. Andersson O., Reissmann E., Ibanez C.F. Growth differentiation factor 11 signals through the transforming growth factor-beta receptor ALK5 to regionalize the anterior-posterior axis. EMBO Rep. 2006, 7:831-837.
155. Rodriguez C., Chen F., Weinberg R.A., Lodish H.F. Cooperative binding of transforming growth factor (TGF)-beta 2 to the types I and II TGF-beta receptors. J. Biol. Chem. 1995, 270:15919-15922.
156. ten Dijke P., Yamashita H., Sampath T.K., Reddi A.H., Estevez M., Riddle D.L., et al. Identification of type I receptors for osteogenic protein-1 and bone morphogenetic protein-4. J. Biol. Chem. 1994, 269:16985-16988.
157. Macias-Silva M., Hoodless P.A., Tang S.J., Buchwald M., Wrana J.L. Specific activation of Smad1 signaling pathways by the BMP7 type I receptor, ALK2. J. Biol. Chem 1998, 273:25628-25636.
158. Hong J.H., Lee G.T., Lee J.H., Kwon S.J., Park S.H., Kim S.J., et al. Effect of bone morphogenetic protein-6 on macrophages. Immunology 2009, 128:e442-e450.
159. Saremba S., Nickel J., Seher A., Kotzsch A., Sebald W., Muller T.D. Type I receptor binding of bone morphogenetic protein 6 is dependent on N-glycosylation of the ligand. FEBS J. 2008, 275:172-183.
160. Harth S. Molecular Recognition in BMP Ligand-receptor Interactions 2010, Julius-Maximilians University Wuerzburg, Wuerzburg.
161. Taylor K.R., Vinci M., Bullock A.N., Jones C. ACVR1 mutations in DIPG: lessons learned from FOP. Cancer Res. 2014, 74:4565-4570.
162. Pignolo R.J., Shore E.M., Kaplan F.S. Fibrodysplasia ossificans progressiva: diagnosis, management, and therapeutic horizons. Pediatr. Endocrinol. Rev. 2013, 10(Suppl. 2):437-448.
163. Bagarova J., Vonner A.J., Armstrong K.A., Borgermann J., Lai C.S., Deng D.Y., et al. Constitutively active ALK2 receptor mutants require type II receptor cooperation. Mol. Cell Biol. 2013, 33:2413-2424.
164. Radaev S., Zou Z., Huang T., Lafer E.M., Hinck A.P., Sun P.D. Ternary complex of transforming growth factor-beta1 reveals isoform-specific ligand recognition and receptor recruitment in the superfamily. J. Biol. Chem. 2010, 285:14806-14814.
165. Groppe J., Hinck C.S., Samavarchi-Tehrani P., Zubieta C., Schuermann J.P., Taylor A.B., et al. Cooperative assembly of TGF-beta superfamily signaling complexes is mediated by two disparate mechanisms and distinct modes of receptor binding. Mol. Cell 2008, 29:157-168.
166. Li J.J., Sugimura S., Mueller T.D., White M.A., Martin G.A., Ritter L.J., et al. Modifications of human growth differentiation factor 9 to improve the generation of embryos from low competence oocytes. Mol. Endocrinol. 2015, 29:40-52.
167. Nickel J., Kotzsch A., Sebald W., Mueller T.D. A single residue of GDF-5 defines binding specificity to BMP receptor IB. J. Mol. Biol. 2005, 349:933-947.
168. Kotzsch A., Nickel J., Seher A., Sebald W., Muller T.D. Crystal structure analysis reveals a spring-loaded latch as molecular mechanism for GDF-5-type I receptor specificity. EMBO J. 2009, 28:937-947.
169. Klammert U., Mueller T.D., Hellmann T.V., Wuerzler K.K., Kotzsch A., Schliermann A., et al. GDF-5 can act as a context-dependent BMP-2 antagonist. BMC Biol. 2015, 13:77.
170. Keller S., Nickel J., Zhang J.L., Sebald W., Mueller T.D. Molecular recognition of BMP-2 and BMP receptor IA. Nat. Struct. Mol. Biol. 2004, 11:481-488.
171. Cash J.N., Rejon C.A., McPherron A.C., Bernard D.J., Thompson T.B. The structure of myostatin:follistatin 288: insights into receptor utilization and heparin binding. EMBO J. 2009, 28:2662-2676.
172. Kirsch T., Sebald W., Dreyer M.K. Crystal structure of the BMP-2-BRIA ectodomain complex. Nat. Struct. Biol. 2000, 7:492-496.
173. Kotzsch A., Nickel J., Seher A., Heinecke K., van Geersdaele L., Herrmann T., et al. Structure analysis of bone morphogenetic protein-2 type I receptor complexes reveals a mechanism of receptor inactivation in juvenile polyposis syndrome. J. Biol. Chem. 2008, 283:5876-5887.
174. Hatta T., Konishi H., Katoh E., Natsume T., Ueno N., Kobayashi Y., et al. Identification of the ligand-binding site of the BMP type IA receptor for BMP-4. Biopolymers 2000, 55:399-406.
175. Klages J., Kotzsch A., Coles M., Sebald W., Nickel J., Muller T., et al. The solution structure of BMPR-IA reveals a local disorder-to-order transition upon BMP-2 binding. Biochemistry 2008, 47:11930-11939.
176. Harth S., Kotzsch A., Hu J., Sebald W., Mueller T.D. A selection fit mechanism in BMP receptor IA as a possible source for BMP ligand-receptor promiscuity. PLoS One 2010, 5.
177. Zuniga J.E., Ilangovan U., Mahlawat P., Hinck C.S., Huang T., Groppe J.C., et al. The TbetaR-I pre-helix extension is structurally ordered in the unbound form and its flanking prolines are essential for binding. J. Mol. Biol. 2011, 412:601-618.
178. Harrison C.A., Gray P.C., Koerber S.C., Fischer W., Vale W. Identification of a functional binding site for activin on the type I receptor ALK4. J. Biol. Chem. 2003, 278:21129-21135.
179. Bocharov E.V., Korzhnev D.M., Blommers M.J., Arvinte T., Orekhov V.Y., Billeter M., et al. Dynamics-modulated biological activity of transforming growth factor beta3. J. Biol. Chem. 2002, 277:46273-46279.
180. Harrington A.E., Morris-Triggs S.A., Ruotolo B.T., Robinson C.V., Ohnuma S., Hyvonen M. Structural basis for the inhibition of activin signalling by follistatin. EMBO J. 2006, 25:1035-1045.
181. Stamler R., Keutmann H.T., Sidis Y., Kattamuri C., Schneyer A., Thompson T.B. The structure of FSTL3: activin A complex. Differential binding of N-terminal domains influences follistatin-type antagonist specificity. J. Biol. Chem. 2008, 283:32831-32838.
182. Thompson T.B., Lerch T.F., Cook R.W., Woodruff T.K., Jardetzky T.S. The structure of the follistatin:activin complex reveals antagonism of both type I and type II receptor binding. Dev. Cell 2005, 9:535-543.
183. Huse M., Chen Y.G., Massague J., Kuriyan J. Crystal structure of the cytoplasmic domain of the type I TGF beta receptor in complex with FKBP12. Cell 1999, 96:425-436.
184. Chaikuad A., Alfano I., Kerr G., Sanvitale C.E., Boergermann J.H., Triffitt J.T., et al. Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressiva. J. Biol. Chem. 2012, 287:36990-36998.
185. Horbelt D., Boergermann J.H., Chaikuad A., Alfano I., Williams E., Lukonin I., et al. Small molecules dorsomorphin and LDN-193189 inhibit myostatin/GDF8 signaling and promote functional myoblast differentiation. J. Biol. Chem. 2015, 290:3390-3404.
186. Han S., Loulakis P., Griffor M., Xie Z. Crystal structure of activin receptor type IIB kinase domain from human at 2.0 Angstrom resolution. Protein Sci. 2007, 16:2272-2277.
187. Kerr G., Sheldon H., Chaikuad A., Alfano I., von Delft F., Bullock A.N., et al. A small molecule targeting ALK1 prevents Notch cooperativity and inhibits functional angiogenesis. Angiogenesis 2015, 18:209-217.
188. Hubbard S.R. Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J. 1997, 16:5572-5581.
189. Johnson L.N., Lowe E.D., Noble M.E., Owen D.J. The Eleventh Datta Lecture: the structural basis for substrate recognition and control by protein kinases. FEBS Lett. 1998, 430:1-11.
190. Endicott J.A., Noble M.E., Johnson L.N. The structural basis for control of eukaryotic protein kinases. Ann. Rev. Biochem. 2012, 81:587-613.
191. Lowe E.D., Noble M.E., Skamnaki V.T., Oikonomakos N.G., Owen D.J., Johnson L.N. The crystal structure of a phosphorylase kinase peptide substrate complex: kinase substrate recognition. EMBO J. 1997, 16:6646-6658.
192. Romano S., D'Angelillo A., Romano M.F. Pleiotropic roles in cancer biology for multifaceted proteins FKBPs. Biochim. Biophys. Acta 2015, 1850:2061-2068.
193. Wang T., Donahoe P.K., Zervos A.S. Specific interaction of type I receptors of the TGF-beta family with the immunophilin FKBP-12. Science 1994, 265:674-676.
194. Shou W., Aghdasi B., Armstrong D.L., Guo Q., Bao S., Charng M.J., et al. Cardiac defects and altered ryanodine receptor function in mice lacking FKBP12. Nature 1998, 391:489-492.
195. Guckian K., Carter M.B., Lin E.Y., Choi M., Sun L., Boriack-Sjodin P.A., et al. Pyrazolone based TGFbetaR1 kinase inhibitors. Bioorg. Med. Chem. Lett. 2010, 20:326-329.
196. Roth G.J., Heckel A., Brandl T., Grauert M., Hoerer S., Kley J.T., et al. Design, synthesis, and evaluation of indolinones as inhibitors of the transforming growth factor beta receptor I (TGFbetaRI). J. Med. Chem. 2010, 53:7287-7295.
197. Kretzschmar M., Liu F., Hata A., Doody J., Massague J. The TGF-beta family mediator Smad1 is phosphorylated directly and activated functionally by the BMP receptor kinase. Genes Dev. 1997, 11:984-995.
198. Lawler S., Feng X.H., Chen R.H., Maruoka E.M., Turck C.W., Griswold-Prenner I., et al. The type II transforming growth factor-beta receptor autophosphorylates not only on serine and threonine but also on tyrosine residues. J. Biol. Chem. 1997, 272:14850-14859.
199. Lee M.K., Pardoux C., Hall M.C., Lee P.S., Warburton D., Qing J., et al. TGF-beta activates Erk MAP kinase signalling through direct phosphorylation of ShcA. EMBO J. 2007, 26:3957-3967.
200. Kettenbach A.N., Wang T., Faherty B.K., Madden D.R., Knapp S., Bailey-Kellogg C., et al. Rapid determination of multiple linear kinase substrate motifs by mass spectrometry. Chem. Biol. 2012, 19:608-618.
201. Lin H.Y., Wang X.F., Ng-Eaton E., Weinberg R.A., Lodish H.F. Expression cloning of the TGF-beta type II receptor, a functional transmembrane serine/threonine kinase. Cell 1992, 68:775-785.
202. Kornev A.P., Haste N.M., Taylor S.S., Eyck L.F. Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:17783-17788.
203. Wrana J.L., Attisano L., Wieser R., Ventura F., Massague J. Mechanism of activation of the TGF-beta receptor. Nature 1994, 370:341-347.
204. Huse M., Muir T.W., Xu L., Chen Y.G., Kuriyan J., Massague J. The TGF beta receptor activation process: an inhibitor- to substrate-binding switch. Mol. Cell 2001, 8:671-682.
205. Abdollah S., Macias-Silva M., Tsukazaki T., Hayashi H., Attisano L., Wrana J.L. TbetaRI phosphorylation of Smad2 on Ser465 and Ser467 is required for Smad2-Smad4 complex formation and signaling. J. Biol. Chem. 1997, 272:27678-27685.
206. Chacko B.M., Qin B.Y., Tiwari A., Shi G., Lam S., Hayward L.J., et al. Structural basis of heteromeric smad protein assembly in TGF-beta signaling. Mol. Cell 2004, 15:813-823.
207. Wu J.W., Hu M., Chai J., Seoane J., Huse M., Li C., et al. Crystal structure of a phosphorylated Smad2: Recognition of phosphoserine by the MH2 domain and insights on Smad function in TGF-beta signaling. Mol. Cell 2001, 8:1277-1289.
208. Shi Y., Hata A., Lo R.S., Massague J., Pavletich N.P. A structural basis for mutational inactivation of the tumour suppressor Smad4. Nature 1997, 388:87-93.
209. Wu G., Chen Y.G., Ozdamar B., Gyuricza C.A., Chong P.A., Wrana J.L., et al. Structural basis of Smad2 recognition by the Smad anchor for receptor activation. Science 2000, 287:92-97.
210. Chen Y.G., Hata A., Lo R.S., Wotton D., Shi Y., Pavletich N., et al. Determinants of specificity in TGF-beta signal transduction. Genes Dev. 1998, 12:2144-2152.
211. Chen Y.G., Massague J. Smad1 recognition and activation by the ALK1 group of transforming growth factor-beta family receptors. J. Biol. Chem. 1999, 274:3672-3677.
212. Feng X.H., Derynck R. A kinase subdomain of transforming growth factor-beta (TGF-beta) type I receptor determines the TGF-beta intracellular signaling specificity. EMBO J. 1997, 16:3912-3923.
213. Yu P.B., Hong C.C., Sachidanandan C., Babitt J.L., Deng D.Y., Hoyng S.A., et al. Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat. Chem. Biol. 2008, 4:33-41.
214. Johnson L.N. Protein kinase inhibitors: contributions from structure to clinical compounds. Q. Rev. Biophys. 2009, 42:1-40.
215. Sanvitale C.E., Kerr G., Chaikuad A., Ramel M.C., Mohedas A.H., Reichert S., et al. A new class of small molecule inhibitor of BMP signaling. PLoS One 2013, 8:e62721.
216. Mohedas A.H., Xing X., Armstrong K.A., Bullock A.N., Cuny G.D., Yu P.B. Development of an ALK2-biased BMP type I receptor kinase inhibitor. ACS Chem. Biol. 2013, 8:1291-1302.
217. Cuny G.D., Yu P.B., Laha J.K., Xing X., Liu J.F., Lai C.S., et al. Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors. Bioorg. Med. Chem. Lett. 2008, 18:4388-4392.
218. Hao J., Ho J.N., Lewis J.A., Karim K.A., Daniels R.N., Gentry P.R., et al. In vivo structure-activity relationship study of dorsomorphin analogues identifies selective VEGF and BMP inhibitors. ACS Chem. Biol. 2010, 5:245-253.
219. Mohedas A.H., Wang Y., Sanvitale C.E., Canning P., Choi S., Xing X., et al. Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants. J. Med. Chem. 2014, 57:7900-7915.